This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)

Tipranks - Tipranks - Sat May 30, 6:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Savara (SVRA) and Biogen (BIIB) with bullish sentiments.

Memorial Day Sale – Claim 70% Off TipRanks

Savara (SVRA)

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Savara, with a price target of $10.00. The company’s shares closed last Thursday at $5.09, close to its 52-week high of $5.34.

According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 2.3% and a 40.0% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as MapLight Therapeutics, Inc., Praxis Precision Medicines, and Centessa Pharmaceuticals. ;'>

Savara has an analyst consensus of Strong Buy, with a price target consensus of $11.17, an 115.6% upside from current levels. In a report issued on May 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.

See the top stocks recommended by analysts >>

Biogen (BIIB)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Biogen, with a price target of $225.00. The company’s shares closed last Thursday at $196.39.

According to TipRanks.com, Amsellem is a 5-star analyst with an average return of 11.4% and a 57.1% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $219.00 average price target, which is an 11.2% upside from current levels. In a report issued on May 15, Evercore ISI also initiated coverage with a Buy rating on the stock.

Read More on SVRA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).